What if one pill could push second-line pancreatic cancer survival past a year? A few years ago that would have sounded like the kind of sentence oncology people say right before someone in the back coughs politely. But as of April 13, 2026, early clinical results around daraxonrasib suggest that answer might actually be yes.[1]
That matters because pancreatic ductal adenocarcinoma is one of cancer’s most stubborn troublemakers. It is fast, sly, and deeply fond of mutations in KRAS, a gene that acts a bit like a growth switch stuck in the “go” position. More than 90% of pancreatic cancers carry a RAS pathway alteration, so researchers have spent years trying to shut that signal down.[2][3] For a long time, KRAS was treated like the final boss with cheat codes turned on. Annoying, untouchable, and way too comfortable.
The Plot Twist in the Pancreas
Daraxonrasib, also known as RMC-6236, is designed to block active RAS, not just one ultra-specific mutation.[2] That broader approach is a big deal in pancreatic cancer, where tumors are genetically messy and rarely inclined to cooperate.
The paper linked here is a short Cancer Discovery news piece, not a full trial report, and that distinction matters. It summarizes two phase I/II studies in metastatic pancreatic cancer and places them next to a bigger headline: on April 13, 2026, Revolution Medicines announced topline results from the phase III RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.[1] In that company report, daraxonrasib was associated with a median overall survival of 13.2 months, compared with 6.7 months for standard chemotherapy in the intent-to-treat population.[1]
If those numbers hold up under full presentation and peer-reviewed publication, that is not a polite little nudge forward. That is a chair-scraping, “wait, read that again” kind of result.
Why Oncologists Are Paying Attention
Pancreatic cancer has needed a win like this for years. Most treatments still rely heavily on chemotherapy, which can help, but often at a cost patients feel in their bones, bellies, mouths, skin, and energy levels. Anyone who has worked around infusion chairs knows the routine is not exactly a spa package.
What makes daraxonrasib interesting is not just that it targets RAS, but that it may do it broadly enough to help more patients than mutation-by-mutation drugs alone. Earlier translational work showed the drug could shrink RAS-driven tumors in preclinical models and produced early responses in patients with KRAS-driven cancers, including pancreatic adenocarcinoma.[2]
There is also a deeper reason people are excited. RAS signaling does not only tell cancer cells to grow. It helps shape the whole tumor neighborhood. In pancreatic cancer, that neighborhood is notoriously hostile - dense scar tissue, immune suppression, bad traffic, no decent exits. A recent preclinical study found that multi-selective RAS inhibition could reduce myeloid-heavy immune suppression and bring more T cells into the tumor microenvironment.[4] In plain English: it may stop the tumor from being such an expert at locking the immune system out of the building.
Not a Victory Parade Yet
Before we start printing “KRAS finally got caught” T-shirts, a reality check.
First, the phase III data were announced by press release and discussed in oncology news coverage, with detailed presentation slated for May 31, 2026 at the ASCO Annual Meeting.[1][5] That means the field still needs the full dataset, subgroup breakdowns, durability details, and peer-reviewed publication.
Second, daraxonrasib is not side-effect-free. Across early studies, common treatment-related side effects included rash, diarrhea, stomatitis or mucositis, nausea, and vomiting.[5] That does not make the drug a failure. It makes it a real cancer drug. Useful drugs often come with baggage. The goal is whether the benefit is worth carrying the suitcase.
Third, pancreatic tumors are crafty little escape artists. Even when KRAS is hit directly, cancer cells can adapt. Research published in 2024 showed that some pancreatic cancer cells slip into a more classical epithelial state that helps them resist KRAS inhibition early on.[6] Translation: even when you finally pick the lock, the tumor may already be halfway out the back window.
Why This Still Feels Different
Even with all those caveats, this moment feels different because pancreatic cancer has spent decades being the disease that humbled nearly everybody. Daraxonrasib is not just another drug with a nice PowerPoint. It is part of a shift from “throw chemo at it and hope” toward “understand the wiring and cut the right cable.”
There is also movement beyond later-line treatment. Early first-line studies presented in 2026 suggested encouraging activity for daraxonrasib both alone and combined with gemcitabine plus nab-paclitaxel, though those trials were small and still early.[5] So the obvious next question is whether this drug works best solo, in combination, or as part of a larger strategy that anticipates resistance before the tumor gets cute.
For patients and families, this kind of news lands differently than it does in a slide deck. More time matters. A treatment that works after prior therapy matters. An oral targeted option matters. Hope that comes with actual numbers attached matters most of all.
And for once, pancreatic cancer may be hearing a sentence it does not enjoy: not today.
References
-
Daraxonrasib Continues Victory Lap. Cancer Discovery. 2026. doi:10.1158/2159-8290.CD-NW2026-0046
-
Jiang J, Jiang L, Maldonato BJ, et al. Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers. Cancer Discovery. 2024;14(6):994-1017. doi:10.1158/2159-8290.CD-24-0027. PMCID:PMC11149917
-
Olson SH, Waters AM. KRAS Inhibition in Pancreatic Ductal Adenocarcinoma. 2025. PMCID:PMC12842425
-
Orlen M, Vostrejs WP, Sor R, et al. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Cancer Discovery. 2025. PMCID:PMC12319402
-
Helwick C. RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer. The ASCO Post. Published April 27, 2026. https://ascopost.com/news/april-2026/ras-inhibitor-daraxonrasib-in-metastatic-pancreatic-cancer
-
Bailey P, Leach BI, Zhu Z, et al. A Classical Epithelial State Drives Acute Resistance to KRAS Inhibition in Pancreatic Cancer. Cancer Discovery. 2024. doi:10.1158/2159-8290.CD-24-0740. PMCID:PMC11624508
Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.